Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/15/2023 | -24.47% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
07/25/2023 | 126.59% | BMO Capital | $11 → $15 | Maintains | Outperform |
06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
06/12/2023 | 35.95% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
05/15/2023 | -32.02% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
03/17/2023 | -9.37% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
01/24/2023 | -39.58% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
08/12/2022 | -24.47% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
08/11/2022 | 66.16% | BMO Capital | $19 → $11 | Maintains | Outperform |
08/11/2022 | -39.58% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
07/15/2022 | 51.06% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
06/17/2022 | 187.01% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
05/24/2022 | 126.59% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
05/24/2022 | 20.85% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
04/05/2022 | 187.01% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
06/23/2021 | 458.91% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
06/22/2021 | 534.44% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
06/22/2021 | 458.91% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
06/22/2021 | 428.7% | Jefferies | → $35 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
2023年08月15日 | -24.47% | 高盛 | $4.5→$5 | 維護 | 中性 |
07/25/2023 | 126.59% | 蒙特利爾銀行資本 | $11→$15 | 維護 | 跑贏大盤 |
2023年6月21日 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
2023/06/12 | 35.95% | 古根海姆 | →$9 | 開始承保 | →購買 |
2023年05月15日 | -32.02% | 高盛 | $4→$4.5 | 維護 | 中性 |
03/17/2023 | -9.37% | SVB Leerink | →$6 | 開始承保 | →跑贏大盤 |
01/24/2023 | -39.58% | 摩根士丹利 | $5→$4 | 維護 | 體重不足 |
2022年08月12日 | -24.47% | 摩根士丹利 | $10→$5 | 評級下調 | 增持→減持 |
2022年08月11日 | 66.16% | 蒙特利爾銀行資本 | $19→$11 | 維護 | 跑贏大盤 |
2022年08月11日 | -39.58% | 高盛 | $5→$4 | 維護 | 中性 |
07/15/2022 | 51.06% | 摩根士丹利 | $15→$10 | 維護 | 超重 |
06/17/2022 | 187.01% | 蒙特利爾銀行資本 | →$19 | 開始承保 | →跑贏大盤 |
2022年05月24日 | 126.59% | 摩根士丹利 | $19→$15 | 維護 | 超重 |
2022年05月24日 | 20.85% | 高盛 | $12→$8 | 維護 | 中性 |
04/05/2022 | 187.01% | 摩根士丹利 | $20→$19 | 維護 | 超重 |
2021/06/23 | 458.91% | 摩根士丹利 | →$37 | 開始承保 | →超重 |
2021/06/22 | 534.44% | 高盛 | →$42 | 開始承保 | →購買 |
2021/06/22 | 458.91% | 摩根士丹利 | →$37 | 開始承保 | →超重 |
2021/06/22 | 428.7% | 傑富瑞 | →$35 | 開始承保 | →購買 |
What is the target price for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的目標價是多少?
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Goldman Sachs on August 15, 2023. The analyst firm set a price target for $5.00 expecting CNTA to fall to within 12 months (a possible -24.47% downside). 7 analyst firms have reported ratings in the last year.
高盛於2023年8月15日報告了Centessa PharmPharmticals(納斯達克代碼:CNTA)的最新目標價。這家分析公司將目標價定為5美元,預計CNTA將在12個月內下跌(可能下跌24.47%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的最新分析師評級是什麼?
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Goldman Sachs, and Centessa Pharmaceuticals maintained their neutral rating.
高盛提供對Centessa PharmPharmticals(納斯達克代碼:CNTA)的最新分析師評級,Centessa PharmPharmticals維持中性評級。
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的下一次分析師評級將於何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Centessa PharmPharmticals的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Centessa製藥的上一次評級是在2023年8月15日提交的,所以你應該預計下一次評級將在2024年8月15日左右的某個時候提供。
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
分析師對Centessa PharmPharmticals(CNTA)的評級正確嗎?
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $4.50 to $5.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.62, which is out of the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但Centessa PharmPharmticals(CNTA)的最新評級保持不變,目標價在4.50美元至5.00美元之間。Centessa PharmPharmticals(CNTA)目前的交易價格為6.62美元,超出了分析師的預測區間。